Today: 7 February 2026
Subscribe

Applied Digital (APLD) Soars on Nov. 20 as Babcock & Wilcox Power Deal, $2.35B Notes Offering and AI “Factory” Buildout Collide

Applied Digital (APLD) Soars on Nov. 20 as Babcock & Wilcox Power Deal, $2.35B Notes Offering and AI “Factory” Buildout Collide

Applied Digital Corporation (NASDAQ: APLD) is back in the spotlight on 20 November 2025, with its stock jumping again as traders digest a wave of news around the company’s ambitious AI data‑center “Factory” strategy, massive new debt financing, and a long‑term power partnership with Babcock & Wilcox (B&W). As of early afternoon trading on Thursday, APLD shares are around $25–26, up roughly 10% on the day versus Wednesday’s close near $23.09, according to real‑time quote data. StockAnalysis The move extends a volatile week in which the AI data‑center specialist has whipsawed on financing headlines but still remains up well over
20 November 2025
····
Micron Stock Today (MU): UBS Lifts Price Target to $275 as AI Memory Boom Collides With Capex Fears – November 20, 2025

Micron Stock Today (MU): UBS Lifts Price Target to $275 as AI Memory Boom Collides With Capex Fears – November 20, 2025

Micron Technology (NASDAQ: MU) is back in the spotlight on Thursday, November 20, 2025, after UBS sharply raised its price target to $275 on the back of an “unusually tight” memory market and booming AI demand — even as investors continue to fret about higher capital spending flagged at a major tech conference this week. Investing As of mid‑afternoon trading, Micron shares are hovering around $220, down roughly 2.5% on the day, but still massively higher year to date after a triple‑digit rally driven by AI data‑center demand and leadership in high‑bandwidth memory (HBM). Barchart Key Takeaways for November 20,
20 November 2025
·····
Cerence (CRNC) Stock Soars After Q4 2025 Earnings Beat and Bold FY26 AI Guidance – November 20, 2025

Cerence (CRNC) Stock Soars After Q4 2025 Earnings Beat and Bold FY26 AI Guidance – November 20, 2025

Cerence Inc. (NASDAQ: CRNC), the automotive voice and AI specialist, is back in the spotlight today after a powerful earnings-driven rally. Following its fiscal Q4 and full-year 2025 report released after the bell on November 19, Cerence stock is surging as investors digest a clean revenue beat, sharply improved cash generation and an ambitious outlook for fiscal 2026 built around generative AI, its xUI cockpit platform and a major patent license deal. Cerence Inc.+2Stock Titan+2 As of early afternoon trading on Thursday, November 20, CRNC is changing hands around $10.95, up about 38% from Wednesday’s close of approximately $7.92, according
20 November 2025
····
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On Wednesday, INM shares closed at $1.23, down almost 16% on the day, before surging about 22% after hours to around $1.50.Benzinga That momentum rolled into Thursday’s pre‑market session, where multiple market data sources showed gains of roughly 20–26%, with INM changing hands in the $1.49–$1.55 range on unusually high volume.Benzinga+2RTTNews+2 As regular trading gets underway, real‑time quote providers still show
20 November 2025
··
Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2 At the time of writing, Nuvation Bio shares trade around $7.15, up roughly 49% today, with an intraday high of $7.21 and heavy trading volume, extending a massive multi‑day rally. Quiver Quantitative Key Takeaways for November 20, 2025 NUVB Stock: From Under‑the‑Radar Biotech to Market Standout The
20 November 2025
····
PACS Group (PACS) Stock Soars as Q3 2025 Earnings, Restatement Cleanup and Bullish Guidance Ignite Rally

PACS Group (PACS) Stock Soars as Q3 2025 Earnings, Restatement Cleanup and Bullish Guidance Ignite Rally

PACS Group, Inc. (NYSE:PACS) is back in the spotlight on Thursday after delivering strong third‑quarter 2025 results, completing a high‑stakes financial restatement process and unveiling upbeat guidance that has sent the stock to fresh 52‑week highs. PACS Group, Inc.+2Stocktwits+2 The post‑acute care operator’s shares have surged this week as investors digest a rare combination of record revenue growth, restored SEC compliance and a series of bullish analyst calls from RBC Capital and Truist Securities. Investing.com+2 As of early afternoon on November 20, PACS stock is trading around $16.83, up sharply over the past week and near its 52‑week high of
20 November 2025
····
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after unveiling a trio of significant updates on November 20, 2025: The moves come as Moderna tries to navigate a steep post‑pandemic revenue reset, heavy R&D spending and investor skepticism about how quickly its broad mRNA pipeline can translate into sustainable
20 November 2025
·····
Stock Market Today, Nov. 20, 2025: Nvidia Rally vs Fed Caution on FOMC Minutes, Trade Gap and Oil

WeShop (WSHP) Stock Today, 20 November 2025: U.S. App Launch, 500% Rally and Sharp Pre‑Market Selloff

WeShop Holdings Limited (NASDAQ: WSHP) is back in the spotlight today, 20 November 2025, as its first U.S. social‑commerce app goes live, the company prepares to ring the Nasdaq Closing Bell in Times Square, and its newly listed shares swing violently after a spectacular 506% surge yesterday. Quiver Quantitative+2 Key points for 20 November 2025 WSHP’s wild first week: from quiet debut to meme‑style rocket Direct listing and first trades WeShop listed on the Nasdaq Capital Market via direct listing on 14 November 2025, with Class A ordinary shares trading under the ticker WSHP. On day one, the stock: FinancialContent+1
20 November 2025
····
Stock Market Today, Nov. 20, 2025: Nvidia Rally vs Fed Caution on FOMC Minutes, Trade Gap and Oil

Stock Market Today, Nov. 20, 2025: Nvidia Rally vs Fed Caution on FOMC Minutes, Trade Gap and Oil

Nvidia’s blockbuster earnings have lit a fire under U.S. stock futures this Thursday, but a hawkish set of Federal Reserve minutes, a sharply narrower U.S. trade deficit and fresh crude oil inventory data are all reminding investors that the macro backdrop is anything but simple. Futures point to a strong open for the Dow, S&P 500 and Nasdaq, even as markets dial back expectations for a December Fed rate cut and digest delayed economic data following the 43‑day government shutdown. Reuters+4TipRanks+424/7 Wall St.+4 Key takeaways for November 20, 2025 Nvidia earnings rekindle the AI trade and power stock futures After
20 November 2025
·····
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of 50 kg of high‑potency iboga bark that is now being processed into ibogaine HCl and full‑spectrum Total Alkaloid Extracts for global clinical and therapeutic markets. GlobeNewswire+1 At the same time, Psyence BioMed’s stock was flagged by Benzinga among Thursday’s top
20 November 2025
···
Bath & Body Works (BBWI) Stock Hit by Q3 2025 Miss, Holiday Sales Warning and New ‘Consumer First’ Turnaround Plan

Bath & Body Works (BBWI) Stock Hit by Q3 2025 Miss, Holiday Sales Warning and New ‘Consumer First’ Turnaround Plan

Bath & Body Works, Inc. (NYSE: BBWI) shares swung wildly on Thursday after the specialty retailer reported softer-than-expected third-quarter 2025 results, slashed its full‑year outlook and warned of weaker holiday demand, even as it unveiled an ambitious new transformation strategy dubbed the “Consumer First Formula.” Finviz+3Reuters+3 As of early afternoon trading, BBWI was changing hands around $21.04 per share, after tumbling as much as mid‑teens percent in pre‑market and early trading. The stock is still down roughly 46% year to date and about 31% over the past 12 months, putting it near multi‑year lows despite a modest intraday rebound. Times
20 November 2025
···
Block, Inc. (XYZ) Stock Jumps on $5 Billion Buyback and Bold 2028 Profit Targets – 20 November 2025

Block, Inc. (XYZ) Stock Jumps on $5 Billion Buyback and Bold 2028 Profit Targets – 20 November 2025

Block, Inc. (NYSE: XYZ) — the Jack Dorsey‑led fintech behind Cash App and Square — is back in the spotlight today after unveiling an ambitious three‑year growth roadmap and a fresh $5 billion share repurchase authorization. The new plan, presented at the company’s 2025 Investor Day, has sent the stock up roughly 7–9% as investors reassess the beaten‑down fintech name. Insider Monkey+3BeInCrypto+3Investors+3 The strategy leans heavily on Block’s two core ecosystems, Cash App and Square, while doubling down on Bitcoin payments, stablecoins and AI‑driven credit and analytics tools. investors.block.xyz+2Digital Transactions+2 Key takeaways for Block, Inc. (XYZ) on 20 November 2025
20 November 2025
·····
1 … 2,109 2,110 2,111 2,112 2,113 … 2,711

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop